3-Cl-PCP
3-chlorophencyclidine
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
3-Cl-PCP (3-chlorophencyclidine) is an emerging synthetic dissociative of the arylcyclohexylamine class. It is a direct structural analog of PCP, distinguished by a single chlorine atom on the phenyl ring. 3-Cl-PCP is a presumed NMDA receptor antagonist, producing its effects by blocking excitatory neurotransmission across memory, sensory, and motor circuits.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
No dose data on record for this route. The timings below are not a dose guide.
ketamine, dextromethorphan, methoxetamine +4 moreketamine, dextromethorphan, methoxetamine, 3-MeO-PCP, PCP, other NMDA antagonists, sigma agonists (SKF-10047) show less
3-Cl-PCP appeared around 2020 and was first formally identified in December 2020 by the Slovenian National Forensic Laboratory.[2][3] It entered circulation alongside other ring-substituted PCP analogs targeting the research chemical market, with no therapeutic or clinical history. It remains unscheduled internationally, though regulatory attention to PCP analogs is intensifying.
Subjective effects include dissociation, depersonalization, motor impairment, and perceptual distortion. The experience is expected to resemble PCP more closely than ketamine — longer-lasting,[4] more stimulating, and with greater psychotomimetic potential.[5] Agitation, confusion, and psychosis-like cognitive disruption are characteristic unsought effects.
Dependence liability is rated moderate for both physical and psychological dimensions,[6] and no toxic dose has been established in any species. The primary risk is psychiatric: PCP-class compounds are among the most potent pharmacological psychotomimetics, and 3-Cl-PCP produced psychosis-like cognitive deficits in the only published behavioral study.[5] The evidence base is critically sparse — a single rodent study constitutes the entirety of substance-specific published knowledge.
History[edit]
Synthesis and emergence
3-Cl-PCP appeared on the novel psychoactive substance market around 2020, originating from Chinese chemical manufacturers and marketed alongside 3-F-PCP and deschloroketamine analogs as part of a new wave of ring-substituted PCP analogs.[3][7] The substance was first formally identified in December 2020 by the Slovenian National Forensic Laboratory, confirmed via mass spectrometry and nuclear magnetic resonance spectroscopy through a forensic toxicology report coordinated with the European Union Early Warning System on drugs.[2][3]
Historical context
PCP was developed in the 1950s as a surgical anesthetic and withdrawn from clinical use in the 1960s due to emergence reactions including agitation, hallucinations, and delirium. Extensive structure-activity relationship work on ring-substituted analogs followed through the 1980s,[8] and methoxy-substituted variants 3-MeO-PCP and 4-MeO-PCP reached the research chemical market around 2011.[9] 3-Cl-PCP is the first chlorine-at-meta-position PCP analog to achieve meaningful distribution as a novel psychoactive substance.
Regulatory timeline
Hungary explicitly banned 3-Cl-PCP in April 2021.[3] In March 2026, the U.S. DEA permanently placed 3-MeO-PCP in Schedule I,[10] establishing regulatory precedent for the ring-substituted PCP analog class. No clinical history exists — 3-Cl-PCP has never been used therapeutically, and no clinical trials have been registered.
Chemistry[edit]
Structural class
3-Cl-PCP belongs to the arylcyclohexylamine chemical class — a cyclohexane ring bonded to both an aromatic ring and an amine nitrogen. The parent scaffold is shared with PCP, ketamine, 3-MeO-PCP, and methoxetamine. The defining modification is a chlorine atom at the 3-position (meta) of the phenyl ring, replacing the unsubstituted phenyl of PCP.
The piperidine ring — a six-membered nitrogen heterocycle — is retained from the parent compound. The IUPAC name is 1-[1-(3-chlorophenyl)cyclohexyl]piperidine.
Molecular properties
| Molecular formula | C₁₇H₂₄ClN |
| Molecular weight | 277.8 g/mol |
The molecular weight is slightly higher than PCP (243.4 g/mol) due to the chlorine substituent. The compound retains the high lipophilicity characteristic of arylcyclohexylamines, driving extensive tissue distribution and prolonged pharmacological activity.
Stereochemistry
The cyclohexyl-phenyl junction carbon bears four distinct substituents, creating a chirality center. No enantiospecific pharmacological data have been published, and the compound is typically characterized as the racemic mixture.
Physical properties
No published characterization of the free base or salt forms exists. By analogy with PCP, the hydrochloride salt is expected to present as a white to off-white crystalline solid. Melting point, solubility, and stability profiles have not been reported.
Pharmacology[edit]
Mechanism of action
3-Cl-PCP is presumed to act primarily through non-competitive antagonism of the NMDA, binding within the open ion channel at the phencyclidine site.[1] This blockade is use-dependent — the channel must be open for the drug to enter — meaning the degree of inhibition scales with ongoing brain activity.[4]
Channel occlusion prevents the flow of charged ions that normally carry excitatory signals between neurons. The result is broad disruption of communication across memory, sensory processing, and motor circuits.
Secondary activity is expected at sigma receptors, which modulate both glutamate and dopamine signaling.[11] Monoamine reuptake inhibitor — affecting dopamine, norepinephrine, and serotonin — contributes the stimulant qualities characteristic of PCP-class compounds.inferred
No substance-specific binding data exist for 3-Cl-PCP. The pharmacological profile is inferred from structural analogy with PCP and from behavioral data in rodents demonstrating a PCP-like profile.[5]
Behavioral pharmacology
The only peer-reviewed study of 3-Cl-PCP (Shaw et al., 2024) tested the compound in mice and rats.[5] 3-Cl-PCP produced locomotor stimulation equal to or greater than PCP — and exceeded methamphetamine and MDMA in effectiveness. It fully substituted for PCP in drug discrimination assays, confirming PCP-like interoceptive effects.
Both PCP and 3-Cl-PCP produced dose-dependent impairment of rule-governed behavior in a cognitive assay, while cocaine and morphine did not — demonstrating specificity for the NMDA antagonist mechanism. Notably, 3-Cl-PCP did not produce lethality at the doses tested, unlike 3-OH-PCP and 3-MeO-PCP.[5]
Pharmacokinetics
No human pharmacokinetic data exist for 3-Cl-PCP. Class-level estimates derive from PCP.
PCP distributes extensively into tissues, with brain concentrations reaching up to 9 times serum levels due to lipophilic partitioning.[4] Plasma half-life averages 17.6 hours but can exceed 2 days in some individuals.[12] Approximately 90% of clearance occurs through liver metabolism, with less than 10% of unchanged drug excreted in urine.[13][14]
Significant stomach-to-blood recirculation has been documented for PCP, with stomach concentrations reaching 50 times serum levels.[4] Whether 3-Cl-PCP shares these characteristics — including the potential for non-linear accumulation with repeated dosing — remains unknown.
Neuroscience[edit]
Where it acts
PCP-class dissociatives disrupt communication between the cortex and deeper brain structures by blocking NMDA receptors on inhibitory interneurons.[1] This produces a paradox: blocking an excitatory receptor actually increases chaotic cortical activity by removing the braking system. The downstream effects include impaired sensory filtering through the thalamus, disrupted memory coordination between prefrontal cortex and hippocampus, and activation of the brain's reward circuitry via secondary dopamine release.[1]
3-Cl-PCP specifically demonstrated disruption of rule-governed cognition in rats — the prefrontal-hippocampal component of this cascade — while cocaine and morphine did not impair the same process.[5]
Why it matters
PCP-induced psychosis provided the original pharmacological model of schizophrenia. Unlike amphetamine psychosis, which reproduces only hallucinations and delusions, NMDA blockade also reproduces social withdrawal, emotional flattening, and cognitive disorganization — making PCP-class compounds central to the NMDA hypofunction hypothesis of psychosis.[1]
Under the predictive processing framework, NMDA receptors help the brain distinguish meaningful signals from noise. Blocking them degrades this filtering, producing aberrant salience, perceptual distortion, and the fragmentation of experience characteristic of dissociative states.[15]
Whether 3-Cl-PCP promotes neuroplasticity — as ketamine does in the context of rapid antidepressant effects — is entirely unknown. The relative contribution of sigma receptor activity to the overall experience has not been isolated.
Subjective Effects[edit]
3-Cl-PCP is expected to produce a dissociative state with a pronounced stimulant edge, driven by combined NMDA blockade and monoamine reuptake inhibitor. Unlike ketamine, which tends toward sedation and shorter duration, PCP-type compounds with intact piperidine rings produce longer-lasting, more activating experiences with greater psychotomimetic potential. Set, setting, and prior dissociative experience are expected to strongly shape the psychological trajectory.
The closest experiential reference point is likely 3-MeO-PCP, though direct comparison is impossible without human data for 3-Cl-PCP. Behaviorally, 3-Cl-PCP aligns with PCP rather than ketamine — rodent drug discrimination confirms PCP-equivalent interoceptive cues.[5]
Effect Grid
A clear dissociative state is established — pronounced cognitive disconnection, depersonalization, and derealization define the psychological landscape. Internal hallucinations may emerge, and perspective distortion alters the apparent geometry of spaces. Visual processing suppression and visual drifting become evident. Vestibular distortion produces a floating or tilting sensation.
Stimulation remains prominent: the body feels energized despite significant motor control impairment. Walking becomes visibly uncoordinated. Pain suppression is strong. Tachycardia and mild hypertension are expected. Spontaneous body sensations, tactile euphoria, and bodily lightness contribute to a complex somatic profile. Excessive sweating and dehydration sensation may occur.
Amnesia for portions of the experience is likely. Thought disorganization and thought deceleration impair coherent reasoning. Immersion enhancement may produce absorbing internal experiences. Compulsive redosing urge may emerge — this should be anticipated and guarded against. The experience commits the user to a prolonged timeline.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Proprioceptive distortion · Ganzfeld effect · Sensory deprivation · Visual drifting · Visual haze / noise · Touch enhancement · Music enhancement · Auditory distortion · Auditory misinterpretation · Color alteration · Peripheral vision distortion · After-images · Auditory suppression · Dreaming suppression · Peripheral misidentification · Tinnitus · Tracers · Visual morphing · Visual processing suppression · Internal hallucinations · Visual scenery slicing · Auditory hallucinations · External hallucinations · Perspective hallucinations · Shadow people · Olfactory hallucination · Persisting hallucinations
Visual drifting · Visual haze / noise · Touch enhancement · Music enhancement · Auditory distortion · Auditory misinterpretation · Color alteration · Peripheral vision distortion · After-images · Auditory suppression · Dreaming suppression · Peripheral misidentification · Tinnitus · Tracers · Visual morphing · Visual processing suppression · Internal hallucinations · Visual scenery slicing · Auditory hallucinations · External hallucinations · Perspective hallucinations · Shadow people · Olfactory hallucination · Persisting hallucinations
Body high · Body schema distortion · Nystagmus (eye wobbles) · Pupil dilation · Restlessness · Spontaneous body sensations · Bodily lightness · Tactile euphoria · Appetite suppression · Dry mouth · Sedation · Wakefulness · Dehydration sensation · Sexual arousal suppression · Excessive sweating · Bodily heaviness · Heart rate perception changes · Insomnia · Laughter fits · Muscle tension · Physical fatigue · Vasoconstriction · Breathing alteration · Bruxism · Headache · Involuntary body movements · Muscle relaxation · Nausea · Tingling / electric sensations · Vibrations / buzzing · Abnormal heartbeat · Respiratory depression · Increased urination · Sexual arousal enhancement · Trembling · Vomiting · Bodily dissociation · Seizure threshold reduction · Tactile hallucination · Phantom limb sensations
Pupil dilation · Restlessness · Spontaneous body sensations · Bodily lightness · Tactile euphoria · Appetite suppression · Dry mouth · Sedation · Wakefulness · Dehydration sensation · Sexual arousal suppression · Excessive sweating · Bodily heaviness · Heart rate perception changes · Insomnia · Laughter fits · Muscle tension · Physical fatigue · Breathing alteration · Bruxism · Headache · Involuntary body movements · Muscle relaxation · Nausea · Tingling / electric sensations · Vibrations / buzzing · Abnormal heartbeat · Respiratory depression · Increased urination · Sexual arousal enhancement · Trembling · Vomiting · Bodily dissociation · Seizure threshold reduction · Tactile hallucination · Phantom limb sensations
Cognitive euphoria · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Immersion enhancement · Thought deceleration · Pattern recognition suppression · Analysis suppression · Thought connectivity · Aesthetic enhancement · Cognitive fatigue · Delusions of sobriety · Introspection enhancement · Motivation suppression · Novelty enhancement · Openness enhancement · Suggestibility enhancement · Thought acceleration · Thought loops · Creativity enhancement · Humor enhancement · Conceptual thinking · Cognitive dysphoria · Language suppression · Multiple thought streams · Motivation enhancement · Amnesia · Delusions · Delirium
Information processing suppression · Memory fragmentation · Immersion enhancement · Thought deceleration · Pattern recognition suppression · Analysis suppression · Thought connectivity · Aesthetic enhancement · Cognitive fatigue · Introspection enhancement · Motivation suppression · Novelty enhancement · Openness enhancement · Suggestibility enhancement · Thought acceleration · Thought loops · Creativity enhancement · Humor enhancement · Conceptual thinking · Cognitive dysphoria · Language suppression · Multiple thought streams · Motivation enhancement · Amnesia · Delusions · Delirium
Emotional enhancement · Emotional lability · Empathy suppression · Anhedonia · Anxiety · Dysphoria · Irritability · Mania
Anhedonia · Anxiety · Dysphoria · Irritability
Sociability suppression · Social disconnection · Communication suppression · Craving · Ego inflation · Sociability enhancement · Cognitive disconnection · Identity alteration · Boundary dissolution · Ego dissolution
Ego inflation · Sociability enhancement · Cognitive disconnection · Identity alteration · Boundary dissolution · Ego dissolution
Transpersonal visions · Death-rebirth sequence · Near-death experience
Timeline
Gradual emergence of first perceptible effects — subtle lightheadedness, faint bodily warmth, and a nascent sense of detachment. Effects build slowly due to the high lipophilicity and extensive tissue distribution characteristic of PCP-class arylcyclohexylamines.
Dissociation and stimulation build steadily. Motor coordination begins to decline, spatial orientation loosens, and a noticeable mood lift or cognitive euphoria emerges. Heart rate increases.
Maximum dissociation, perceptual distortion, and cognitive disruption. Internal hallucinations, depersonalization, and profound motor impairment define this phase. Stimulation remains prominent.
Sustained dissociative plateau at reduced but still significant intensity. Cognitive fog, amnesia, and motor impairment persist. The stimulant component may sustain wakefulness and restlessness.
Gradual return toward baseline. Residual stimulation, cognitive fog, and mild perceptual distortion linger. Motor coordination improves slowly.
Prolonged residual effects — cognitive impairment, physical fatigue, mood instability, and subtle perceptual shifts may persist for hours to days. Sleep architecture disruption is common.
⚠ Do not drive or operate machinery for at least 24 hours after use; PCP-class compounds produce prolonged cognitive and motor impairment that may outlast subjective effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · dextromethorphan · methoxetamine
Toxicity
No controlled toxicity data exist for 3-Cl-PCP. The toxic dose is unknown in all species.
Acute toxicity
In the only published animal study, 3-Cl-PCP did not cause death at the doses tested — distinguishing it from 3-OH-PCP and 3-MeO-PCP, both of which produced fatalities.[5] This does not establish safety; it reflects only the limited dose range examined.
Computer modeling for related PCP analogs estimates lethal doses in rats at approximately 200–630 mg/kg orally and 25–59 mg/kg intravenously in mice.[16] These predictions carry significant uncertainty and have not been validated for 3-Cl-PCP.safety citation needed
Heart and circulation
PCP-class compounds produce elevated heart rate and blood pressure through stimulation of the sympathetic nervous system.[4] Computer modeling predicts potential for heart rhythm disruption via hERG channel inhibition.[16]safety citation needed
Muscle breakdown and kidney injury
Muscle breakdown and acute kidney injury have been documented for 3-methyl-PCP, a closely related analog.[17] PCP-class compounds produce sustained involuntary muscle contraction, agitation, and overheating — all established contributors to this risk. This applies to 3-Cl-PCP by class membership.
Liver toxicity
Computer modeling predicts the liver as a target organ for PCP analogs.[16] PCP is converted to reactive intermediates in the liver,[13] a pathway that could generate toxic metabolites. No clinical liver toxicity data exist for 3-Cl-PCP.safety citation needed
Brain toxicity
Chronic NMDA blocker exposure produces damage to specific brain regions in rodent models. Long-term cognitive impairment and brain white matter abnormalities are documented in chronic ketamine users, establishing precedent for cumulative brain damage within this drug class.citation needed
Psychological risks
Psychosis is the principal psychological risk. PCP is among the most potent drug-induced psychosis triggers, producing hallucinations, delusions, social withdrawal, emotional flattening, and thought disorganization.[1] 3-Cl-PCP produced dose-dependent psychosis-like cognitive deficits in a rat model designed for validity against the human psychosis construct.[5]
Prolonged psychiatric effects are documented for the closely related 3-MeO-PCP, with hallucinations persisting up to six weeks after a single exposure.[18] A case report documents attempted murder under the combined influence of 3-MeO-PCP and MDPV.[18] No equivalent case reports exist for 3-Cl-PCP, but the shared pharmacological class indicates comparable risk.
Agitation and violence are characteristic of PCP-class intoxication, driven by the convergence of dissociation, dopamine-driven disinhibition, and pain insensitivity that removes behavioral restraint.[4]
No published human case reports of 3-Cl-PCP intoxication exist.[2]
Tolerance & dependence
Tolerance develops rapidly to PCP-class compounds. In rats, continuous PCP infusion produced tolerance to motor-impairing effects within 3.5 days, with greater than 2-fold shift in dose-response curves.[6] In monkeys, approximately 2-fold tolerance developed after 82–126 days of chronic dosing.[19]
Cross-tolerance is documented between PCP and sigma agonists[20] and is expected across the dissociative class, including ketamine, dextromethorphan, and other NMDA antagonists.
Physical dependence has been demonstrated for PCP in rats after 7 days of continuous infusion; withdrawal included hair standing on end, seizures triggered by loud sounds, weight loss, and reduced activity, emerging approximately 4 hours after cessation.[6]
PCP reliably maintains self-administration in animal models, confirming genuine addictive potential.[8] Both physical and psychological dependence are rated moderate for 3-Cl-PCP based on class data. No tolerance, dependence, or withdrawal data specific to 3-Cl-PCP have been published.
Drug interactions
No published interaction data exist for 3-Cl-PCP. All interactions are extrapolated from PCP and arylcyclohexylamine class pharmacology.
CNS depressants (alcohol, benzodiazepines, opioids, GHB) produce additive sedation and respiratory depression. Polydrug use was identified in 53% of ketamine-related deaths in a systematic review[21] — the highest-risk interaction category for the class.
Stimulants (amphetamines, cocaine, MDMA) combined with PCP-class compounds produce compounded dopamine activation, increasing risk of dangerously elevated blood pressure, overheating, and acute psychosis.
Lithium combined with dissociatives increases seizure risk.[22]
MAOIs combined with PCP-class compounds risk serotonin syndrome via the monoamine reuptake inhibitor component of PCP pharmacology.
Serotonergic agents (tramadol, SSRIs, SNRIs) combined with NMDA antagonists that also inhibit serotonin reuptake may increase serotonin syndrome risk, though direct evidence for 3-Cl-PCP is absent.
Contraindications
Pre-existing psychotic disorders: NMDA receptor antagonists exacerbate schizophrenia spectrum symptoms. 3-Cl-PCP is contraindicated in individuals with schizophrenia, schizoaffective disorder, or a personal or family history of psychosis.[1]
Heart conditions: Sympathomimetic effects and predicted heart rhythm disruption represent serious risk for individuals with pre-existing cardiac conditions or high blood pressure.[16]
Concurrent CNS depressant use: The combination with breathing-suppressing drugs (opioids, benzodiazepines, alcohol, GHB) carries life-threatening risk. Polydrug involvement accounts for the majority of dissociative-related deaths.[21]
Concurrent stimulant use: Combined dopamine activation may produce unpredictable cardiovascular stress and psychiatric destabilization.
Pregnancy and lactation: No reproductive data exist. Contraindicated by class analogy.safety citation needed
Liver impairment: PCP-class compounds undergo near-complete liver metabolism (~90%); significant liver dysfunction could produce dangerous drug accumulation.inferred
Kidney impairment: Muscle breakdown risk and potential for acute kidney injury warrant caution in individuals with pre-existing kidney disease.inferred
Harm Reduction[edit]
Forms & Identification
3-Cl-PCP circulates exclusively through the research chemical market, where product identity and purity are unverified by default. The compound is a structural analog of PCP — a single chlorine atom is the only distinguishing feature — and cannot be reliably differentiated from other PCP analogs by appearance, taste, or smell alone. Independent laboratory analysis (such as energy-dispersive X-ray spectroscopy or mass spectrometry via services like DrugsData or WEDINOS) is the only way to confirm identity.
Standard reagent kits provide limited discrimination within the arylcyclohexylamine class. A negative fentanyl test strip result does not confirm safety or identity — it only excludes fentanyl contamination.
Guidelines
- Test every batch. Use reagent testing and, where possible, laboratory analysis to confirm substance identity. Do not assume consistency between batches.
- Start extremely low. No human dose range has been established for 3-Cl-PCP. Begin with the smallest amount that can be accurately measured and wait the full expected onset window before considering any additional dose.
- Do not redose. PCP-class compounds have long durations and may accumulate non-linearly with repeated dosing. Redosing before effects fully resolve risks dangerous accumulation.
- Use volumetric dosing. Powder quantities at the milligram scale cannot be accurately divided by eye. Dissolve a known amount in a measured volume of solvent and dose by volume.
- Avoid all combinations. CNS depressants, stimulants, lithium, MAOIs, and serotonergic medications all carry dangerous interaction potential with PCP-class compounds.
- Ensure a sober sitter is present. Dissociative crises can escalate unpredictably. The sitter should know what substance was taken and when.
- Secure the environment. Remove sharp objects, lock windows and doors to balconies, and restrict access to vehicles. Pain insensitivity during intoxication removes normal self-protective behavior.
Set & Setting
PCP-class dissociatives carry pronounced psychotomimetic potential. The risk of agitation, paranoia, and psychotic reactions increases substantially in unfamiliar, chaotic, or high-stimulation environments. A calm, controlled, private setting with minimal external demands is strongly recommended.
A sober, trusted companion who understands dissociative crisis presentation is essential. PCP-class intoxication can produce pain insensitivity and loss of behavioral restraint — the affected person may not recognize danger or respond to verbal de-escalation. Prior dissociative experience and stable psychological baseline reduce but do not eliminate psychiatric risk.
Aftercare & integration. Dissociative experiences — particularly with PCP-class compounds — can leave lasting cognitive and emotional residue. Feelings of unreality, detachment, or confusion may persist for hours to days after the primary effects have resolved. Allow adequate time for full cognitive recovery before resuming responsibilities that require focused attention, driving, or decision-making.
If dissociative symptoms (feeling detached from your body or surroundings, difficulty distinguishing reality from memory) persist beyond 48 hours, consult a healthcare provider. Prolonged psychiatric effects lasting weeks have been documented with related compounds. Journaling the experience and discussing it with a trusted person can help reground and process unusual perceptual states.
Recovery & Support
PCP-class dissociatives carry moderate abuse liability. Patterns of escalating use, compulsive redosing despite negative consequences, or using to manage emotional distress are indicators of problematic use. Cross-tolerance across dissociatives means that switching compounds does not reset dependence risk.
Professional support options include addiction counselors experienced with dissociative or novel psychoactive substance use, psychiatrists who can address co-occurring conditions, and peer support communities. SAMHSA’s National Helpline (1-800-662-4357) provides free, confidential referrals. In crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Severe agitation or combative behavior that cannot be verbally de-escalated
- Seizures or sustained involuntary muscle rigidity
- Chest pain, irregular heartbeat, or difficulty breathing
- Loss of consciousness or unresponsiveness
- Self-harm behavior or complete disconnection from reality
- Body temperature that feels dangerously hot to the touch
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present.
- 2. Do not physically restrain the person unless there is immediate risk of self-harm or harm to others — restraint can worsen agitation and increase muscle breakdown risk.
- 3. Move the person to a quiet, low-stimulation environment if safely possible.
- 4. Place an unconscious person in the recovery position (on their side, airway clear).
- 5. Do not induce vomiting.
- 6. Monitor breathing and body temperature continuously until help arrives.
What to tell the dispatcher: Name the substance (3-Cl-PCP, a PCP analog), the amount if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for PCP-class dissociatives. Treatment is supportive.
Legal Status[edit]
3-Cl-PCP exists in a regulatory gray zone characteristic of novel arylcyclohexylamine analogs. It is not named in any international drug control convention and is not specifically scheduled in most national jurisdictions. Its structural relationship to PCP — a Schedule II substance in the United States and Schedule I under the 1971 UN Convention on Psychotropic Substances — subjects it to analog legislation in several countries.[23] Regulatory attention to this compound class is intensifying, as demonstrated by the permanent scheduling of 3-MeO-PCP in the United States in 2026.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; subject to Federal Analogue Act | As a structural analog of PCP (Schedule II), 3-Cl-PCP is treated as Schedule I when intended for human consumption under 21 U.S.C. § 813inferred |
| United Kingdom | Covered by Psychoactive Substances Act 2016 | Supply, production, and importation are criminal offenses; not separately listed under the Misuse of Drugs Act 1971citation needed |
| Hungary | Illegal | Explicitly banned since April 2021[3] |
| International (UN) | Not scheduled | Not named in the 1971 Convention on Psychotropic Substances; PCP and named analogs are Schedule I[23] |
Legal status in Australia, Canada, Germany, and other EU member states has not been confirmed. Given the pace of novel psychoactive substance scheduling globally, the legal status of 3-Cl-PCP may change without notice.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcdefghiShaw HE, Patel DR, Gannon BM, Fitzgerald LR, Carbonaro TM, Johnson CR, Fantegrossi WE (2024) Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents — The Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.123.001942
- [6] ^abcSpain JW, Klingman GI (1985) Continuous intravenous infusion of phencyclidine in unrestrained rats results in the rapid induction of tolerance and physical dependence — Journal of Pharmacology and Experimental Therapeutics PMID:4040569